PP
PPBT.US Purple Biotech
- Market cap
- USD 2.78M
- P/E
- -
- P/B
- 0.22x
- ROE
- 5.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PPBT.US undervalued?
Graham numberThe Graham number of Purple Biotech cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Purple Biotech fundamental analysis
No fundamental analysis for Purple Biotech yet.
Purple Biotech stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarc…
Full company profilePurple Biotech financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Purple Biotech annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 100K | 1.00M | 1.00M | 1.00M | -320K | -910K | 196K | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | 100K | 1.00M | 1,000K | -237K | -55.00 | -120.00 | -196.00 | -186K | -205K | - |
| Operating Income | -7.18M | -12.0M | -7.83M | -7.16M | -13.3M | -17.9M | -22.6M | -22.3M | -11.0M | -27.5M | -7.10M |
| EBITDA | -7.04M | -12.9M | -5.55M | -6.14M | -13.1M | -17.5M | -21.5M | -19.7M | -7.05M | -26.3M | 1.05M |
| Net Income | -12.1M | -12.2M | -5.20M | -5.85M | -28.2M | -18.4M | -21.7M | -19.9M | -7.24M | -26.4M | 710K |
| EPS | -421 | -258 | -73 | -60 | -49 | -21 | -24 | -18 | -4.42 | -5.50 | 0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 14.9M | 14.2M | 14.7M | 14.7M | 83.8M | 70.2M | 54.6M | 44.3M | 37.0M | 17.6M | 14.2M |
| Total Liabilities | 1.53M | 5.59M | 3.72M | 3.86M | 4.05M | 5.09M | 7.52M | 10.0M | 4.13M | 7.91M | 1.95M |
| Shareholders' Equity | 13.4M | 7.31M | 10.5M | 10.4M | 79.4M | 64.8M | 46.9M | 34.2M | 32.9M | 9.71M | 12.3M |
| Cash & Short-term Investments | 14.7M | 3.95M | 5.16M | 6.40M | 57.8M | 47.2M | 32.1M | 15.4M | 8.52M | 9.57M | 6.11M |
| Total Debt | - | - | - | 223K | 895K | 749K | 515K | 351K | 183K | 244K | 134K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.26M | -8.63M | -8.48M | -5.58M | -12.1M | -15.3M | -16.7M | -19.9M | -14.4M | -5.54M | -11.2M |
| Capital Expenditure | 10.0K | 13.0K | 16.0K | 11.0K | 156K | 115K | 228K | 3.00K | 0.00 | 3.03K | 0.00 |
| Free Cash Flow | -6.27M | -8.64M | -8.50M | -5.59M | -12.2M | -15.4M | -17.0M | -19.9M | -14.4M | -5.54M | -11.3M |
| Ratios | |||||||||||
| ROE | -90.6% | -166.5% | -49.4% | -56.1% | -35.5% | -28.4% | -46.2% | -58.1% | -22.0% | -271.6% | 5.8% |
| ROA | -81.3% | -85.9% | -35.3% | -39.7% | -33.6% | -26.2% | -39.7% | -44.9% | -19.5% | -150.2% | 5.0% |
| Net Profit Margin | - | -12,177.0% | -520.0% | -585.0% | -2,819.5% | - | - | -10,153.0% | - | - | - |
| Debt to Equity | - | - | - | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.03x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Purple Biotech dividends
Purple Biotech has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Mar 2, 2026.
Who owns Purple Biotech
- Insiders 0.00%
- Institutions 10.88%
- Public & others 89.12%
- Shares outstanding 1.63M
- Free float 1.08M
Top funds holding PPBT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 633.00 | 0.04% | 0.00% | Oct 2024 |
Top institutions holding PPBT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SmartHarvest Portfolios, LLC | 28.5K | 1.75% | +57.05% | Jun 2026 |
| HRT FINANCIAL LLC | 14.6K | 0.90% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 13.2K | 0.81% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 12.8K | 0.79% | -75.94% | Jun 2026 |
| Independent Advisor Alliance | 11.9K | 0.73% | 0.00% | Jun 2026 |
| SRS Capital Advisors Inc | 1.45K | 0.09% | 0.00% | Jun 2026 |
| Rhumbline Advisers | 850.00 | 0.05% | -0.70% | Sep 2026 |
| UBS Group AG | 751.00 | 0.05% | +658.59% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 197.00 | 0.01% | -65.92% | Jun 2026 |
| Royal Bank of Canada | 128.00 | 0.01% | +1,180.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 8.00 | 0.00% | 0.00% | Jun 2026 |
| IFG Advisory, LLC | 7.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 3.00 | 0.00% | -90.32% | Jun 2026 |
| SIMPLEX TRADING, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Global Retirement Partners, LLC. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Danske Bank A/S. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Group One Trading, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisory Services Network, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
Purple Biotech company profile
- Company name
- Purple Biotech
- Ticker
- PPBT.US
- Exchange
- USA Stocks
- Listed since
- Nov 20, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 4 Oppenheimer Street, Rehovot, Israel, 7670104
- Phone
- 972 3 933 3121
- Website
- purple-biotech.com
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Purple Biotech management
4- Mr. Isaac IsraelInterim Chief Executive Officer & Director · born 1978
- Mr. Shai Lankry CPA, M.B.A.Chief Financial Officer · born 1976
- Mr. Gil Efron CPA, M.A.Head of Corporate Development & Executive Director · born 1966
- Dr. Michael Schickler Ph.D.Head of Clinical & Regulatory Affairs · born 1958